Annual report to the nation on the status of cancer, part 1: National cancer statistics

Abstract

Background: The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods: Data on new cancer diagnoses during 2001-2018 were obtained from the North American Association of Central Cancer Registries' Cancer in North America Incidence file, which is comprised of data from Centers for Disease Control and Prevention-funded and National Cancer Institute-funded, populationbased cancer registry programs. Data on cancer deaths during 2001-2019 were obtained from the National Center for Health Statistics' National Vital StatisticsSystem. Five-year average incidence and death rates along with trends for all cancers combined and for the leading cancer types are reported by sex, racial/ ethnic group, and age.Results: Overall cancer incidence rates were 497 per 100,000 among males (ranging from 306 among Asian/Pacific Islander males to 544 among Black males) and 431 per 100,000 among females (ranging from 309 among Asian/ Pacific Islander females to 473 among American Indian/Alaska Native females) during 2014-2018. The trend during the corresponding period was stable among males and increased 0.2% on average per year among females, with differing trends by sex, racial/ethnic group, and cancer type. Among males, incidence rates increased for three cancers (including pancreas and kidney), were stable for seven cancers (including prostate), and decreased for eight (including lung and larynx) of the 18 most common cancers considered in thisThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Annual report to the nation on the status of cancer

“…show that combining metastasis-directed radiation therapy (MDRT) with intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. 1 These results from the multicenter EXTEND trial, a phase 2 randomized basket trial for multiple solid tumors assessing whether adding MDRT improves PFS in patients with oligometastatic cancer, represent the first randomized evidence of patient outcomes with radiation therapy and hormone therapy.…”

Construction of IL-1 signalling pathway correlation model in lung adenocarcinoma and association with immune microenvironment prognosis and immunotherapy: Multi-data validation

“…The mortality rate is 18.0% (3), with non-small cell lung cancer (NSCLC) ranking first among malignant tumours in terms of incidence and mortality (4). The main pathological types include adenocarcinoma, squamous carcinoma and large cell carcinoma, which account for more than 85% of all lung cancers and have a 5year survival rate of about 16% (5)(6)(7). Patients with advanced lung adenocarcinoma have a low survival rate (overall survival, OS) (8).…”

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis

“…Although mortality has steadily decreased since 1990, colorectal cancer remains one of the most frequent cancerrelated death in the US (1). In addition, the incidence of colorectal cancer under the age of 50 increased from 1992 to 2012 at a rate of 2.1% annually, and continues to rise (2).…”